个人简介

Ph.D. (Biochemistry), University of Cambridge MSc, Medical Biochemistry, University of Calgary BSc, Biological Sciences, University of Lethbridge

研究领域

Understanding how cancer cells divide, Checkpoint adaptation

The Cancer Cell Laboratory focuses on two projects: 1. The Prairie to Pharmacy Project. We are investigating plant species from the prairie ecological zone for novel anti-cancer compounds. This is a multidisciplinary project that includes collaborators with international pharmaceutical companies. 2. Checkpoint Adaptation project. We examine how cancer cells respond to cancer treatments. We are testing the hypothesis that cancer cells undergo a pathway known as "checkpoint adaptation" (entering mitosis with damaged DNA). We use cultured human cells and cell biological techniques such as microscopy, RNA interference, transfection and Western blotting.

近期论文

查看导师最新文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Lewis, C.W. and R.M. Golsteyn. Cancer cells that survive checkpoint adaptation contain micronuclei that harbour damaged DNA. Cell Cycle. In press 2016. 2. Swift, L.H. and R.M. Golsteyn. Cytotoxic amounts of cisplatin induce either checkpoint adaptation or apoptosis in a concentration dependent manner in cancer cells. Biology of the Cell. 108:127-148. 2016. 3. Swift, L.H. and R.M. Golsteyn. "The relationship between checkpoint adaptation and mitotic catastrophe in genomic changes in cancer cells." In Genome Stability. Ed. Kovalchuk, I. and Kovalchuk, O. Elsevier, 2016 4. Golsteyn, R.M. Cyclin Dependent Kinases (Cdks), Encyclopedia of Cancer, Springer, M. Schwab. Ed. 3rd Edition 2015. 5. Lewis, C.W., R.G. Taylor, and R.M. Golsteyn. "Measurement of Cdk1/cyclin B kinase activity by specific antibodies and western blotting." Methods in Molecular Biology. 1342:337-348. 2015. 6. Kernéis, S., L.H. Swift, C.W. Lewis, C. Bruyère, N. Oumata, P. Colas, S. Ruchaud, J. Bain and R.M. Golsteyn. "Natural product extracts of the Canadian prairie plant, Thermopsis rhombifolia, have anti-cancer activity in phenotypic cell based assays." Natural Product Research. 29:1026-1034. 2015. 7. Swift, L.H. and R.M. Golsteyn. "Genotoxic anti-cancer agents and their relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer cells." International Journal of Molecular Sciences 15:3403-3431. 2014. 8. Lewis, C.W., R.G. Taylor, P.M. Kubara, K. Marshall, L. Meijer, and R.M. Golsteyn. "A western blot assay to measure cyclin dependent kinase activity in cells or in vitro without the use of radioisotopes." FEBS Letters 587:3089-3095. 2013. 9. Kubara, P.M., S. Kernéis, A. Studeny, B. Lanser, L. Meijer and R.M. Golsteyn. "Human cells enter mitosis with damaged DNA after treatment with pharmacological concentrations of genotoxic agents." Biochemical Journal, 446:373-381. 2012. 10. Perron-Sierra, F.M., N. Kucharkzyk, C. Boucley, C. Guyard-Daumas, S. Sciberras, C. Fouache, A. Studény, C. Bossard, P.J. Casara and R.M. Golsteyn. "Synthesis of cis-fused pyran indolocarbazole derivatives that inhibit FLT3 kinase and the DNA Damage Kinase, checkpoint kinase 1." Anti-Cancer Agents and Medicinal Chemistry 12:194-201. 2012. 11. Ferry, G., A. Studény, C. Bossard, P.M. Kubara, D. Zeyer, J.-P. Renaud, P. Casara, G. de Nanteuil, M. Wierzbicki, B. Pfeiffer, M. Prudhomme, S. Leonce, A. Pierré, J.A. Boutin, and R.M. Golsteyn. "Identification and characterization of novel Checkpoint kinase 1 inhibitors by in vitro and cell based screening." Life Sciences. 89:259-268. 2011.